Table 3.
Adverse events associated with treatment with bosutinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.
| Adverse events | Grade 3/4 (%) | All grades (%) |
|---|---|---|
| Nonhematological | ||
| Diarrhea | 8 | 81 |
| Nausea | 1 | 46 |
| Vomiting | 3 | 39 |
| Fatigue | 2 | 23 |
| Rash | 7 | 33 |
| Increased ALT | 7 | 17 |
| Increased AST | 4 | 14 |
| Hematological | ||
| Anemia | 12 | 24 |
| Thrombocytopenia | 24 | 33 |
| Leukopenia | 11 | 15 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.